← board
SPRY
ARS Pharmaceuticals, Inc.distress 2/10 · well-funded / low risk$5.88-3%today-68% from 52w high
Lead: chronic spontaneous urticaria
Revenue
$23M
Liquidity
$201M
Runway
1.1 yrs
Shares 1y
+1%
Price & events
-44.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.0%
1D
-21.2%
1W
-42.8%
1M
-29.2%
3M
-42.4%
6M
-67.3%
1Y
-43.0%
2Y
-82.0%
5Y
-85.1%
All
Overview
- Market Cap
- $583.90M
- Enterprise Value
- $656.10M
- Volume
- 337.78K
- 52 Week Range
- $5.88 – $18.35
- Total Shares
- 99.30M
- Float Shares
- 48.43M
- Short %
- 31.58%
- % Held by Insiders
- 16.21%
- % Held by Institutions
- 95.67%
- RVOL
- 0.17x
- Beta
- 0.88
Pipeline stages · 1 programs
0.5 mg epinephrine, 1 mg epinephrine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06 | Phase 2 | 0.5 mg epinephrine, 1 mg epinephrine | Urticaria Chronic | 42 | recruiting |
Catalyst news & presentations · 11
- mid-2027Guided 55%trial initiationsecondaryPhase 3neffy (intranasal epinephrine) · Potential initiation of single Phase 3 pivotal efficacy studySEC 8-K
- fourth quarter of 2026Guided 70%readoutPhase 2neffy (intranasal epinephrine) · Interim analysis of Phase 2b trial in CSUSEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 2neffy · Topline data from Phase 2b trial of intranasal epinephrine technology.SEC 8-K
- first half of 2026chmp opinionCHMP (EU)EUR neffy 1 mg · EMA approval anticipated for 1 mg dose.SEC 8-K
- first half of 2026regulatory submissionFiled (NDA/BLA)neffy · Regulatory approval expected in China.SEC 8-K
- first quarter of 2026regulatory submissionFiled (NDA/BLA)neffy · Regulatory approval expected in Canada.SEC 8-K
- fourth quarter of 2025conferencedata presentationsecondaryneffy · neffy available in Japan via Alfresa.SEC 8-K
- March 6, 2025PDUFAPDUFAneffy · PDUFA target action date for neffy 1 mg sNDASEC 8-K
- January 15, 2025conferencedata presentationsecondaryCompany overview at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- by the end of the third quarter of 2024regulatory submissionFiled (NDA/BLA)neffy · file sNDA for neffy 1 mg for pediatric patientsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $27 (+355% upside) · 4 analysts
- 2026-06-25Leerink PartnersOutperform
- 2026-05-28Cantor FitzgeraldOverweight
- 2025-09-04Roth CapitalBuy
- 2025-03-07ScotiabankSector Outperform
- 2025-01-14Raymond JamesStrong Buy
- 2025-01-13Leerink PartnersOutperform
Competitors — chronic spontaneous urticaria
Recent news
- 2026-07-23(SPRY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
- 2026-07-17ARS Pharmaceuticals (NASDAQ: SPRY) reports board resignation and CMO exit - Stock Titan
- 2026-07-16INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY - PR Newswire
- 2026-07-15ARS Pharmaceuticals (SPRY) Appoints Donn Casale As The New CEO - Yahoo Finance
- 2026-07-14Millennium group discloses ARS Pharmaceuticals (SPRY) ownership below 5% - Stock Titan
- 2026-07-13Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out - ACCESS Newswire
- 2026-07-132026-07-13 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ARS Pharmaceuticals, Inc. (SPRY) And Encourages Shareholders to Reach Out | NDAQ:SPRY | Press Release - Stockhouse
- 2026-07-11(SPRY) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.